- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07946848
Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.
A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: IMM1104-201 Study Team
- Telefonnummer: (860) 321-1302
- E-post: clinicaltrials@immuneering.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Aged 18 years or older
- Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or metastatic disease. Prior adjuvant or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence.
- Measurable disease (at least 1 target lesion) per RECIST 1.1.
- ECOG performance status of 0 or 1.
- PD-L1 score determined by an FDA-approved test.
- RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid biopsy is acceptable.
- Adequate organ function:
Exclusion Criteria:
- Inability to swallow oral medications.
- EGFR, ALK or ROS1 mutation.
- Untreated or unresolved brain metastases
- Encephalitis, meningitis or uncontrolled seizures in the year before informed consent.
- History of interstitial lung disease non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids, or any pneumonitis within the last 5 years. Radiation pneumonitis in the radiation field is permitted.
- Active autoimmune disease that required systemic treatment in the past 12 months.
- A condition requiring corticosteroids >10 mg/day prednisone or equivalent within 14 days of Cycle 1 Day 1.
- Prior allogeneic tissue or solid organ transplant.
- Never-smoker (fewer than 100 cigarettes in a lifetime).
- Prior anti-PD-1 or anti-PD-L1 therapy.
- Impaired cardiac function or clinically significant cardiac disease, including left ventricular ejection fraction <50% by ECHO or MUGA or screening QTcF >470 msec.
- History of serous retinopathy, retinal edema or retinal pigment epithelial detachment.
- History or current evidence of retinal vein occlusion (RVO), or current RVO risk factors.
- Rhabdomyolysis within 3 months before Study Day 1.
- Major surgery or significant traumatic injury within 4 weeks before the first dose.
- Another malignancy.
- Any infection requiring hospitalization or IV anti-infectives within 2 weeks before the first dose.
- Uncontrolled HIV, hepatitis B or hepatitis C infection; immunodeficiency; or active or latent tuberculosis.
- Live vaccine within 4 weeks before the first dose.
- COVID-19 vaccination within 1 week before the planned first dose, or a planned COVID-19 vaccination series that won't be completed at least 1 week before the first dose.
- Known hypersensitivity to any study drug or excipient.
- Unwillingness to use effective contraception
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Atebimetinib + Cemiplimab ± Chemotherapy
Participants receive atebimetinib orally once daily (160, 240 or 320 mg) plus cemiplimab 350 mg IV every 3 weeks. Carboplatin and pemetrexed are given IV every 3 weeks for 4 cycles in the dose optimization portion, and in the expansion portion for participants with PD-L1 <50%. The expansion uses the atebimetinib dose selected during dose optimization. |
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
Andre navn:
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
Andre navn:
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4 500 mg/m² IV on Day 1 of Cycles 1-4
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of Atebimetinib
Tidsramme: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
Measured in dose optimization |
Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
|
Objective Response Rate (ORR)
Tidsramme: Every 8 weeks, up to approximately 24 months
|
Percentage of participants with complete or partial response per RECIST 1.1 |
Every 8 weeks, up to approximately 24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Median Progression-Free Survival (PFS)
Tidsramme: Up to approximately 24 months.
|
Time from Cycle 1 Day 1 to first documented disease progression per RECIST v1.1 or death from any cause, whichever comes first. |
Up to approximately 24 months.
|
|
Overall Survival (OS)
Tidsramme: From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
Time from Cycle 1 Day 1 to death from any cause. |
From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
|
Number of Participants with adverse events
Tidsramme: From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Treatment-emergent and treatment-related AEs per CTCAE v6.0 |
From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Vinny Hayreh, Immuneering Corporation
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Aminosyrer, peptider og proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Koordinasjonskomplekser
- Guanin
- Hypoksantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sure
- Aminosyrer
- Aminosyrer, dikarboksyl
- Pemetrexed
- Karboplatin
- Cemiplimab
Andre studie-ID-numre
- IMM1104-201
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .